Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.

The pharmacogenomics journal - 1 Jan 2004

Fukunaga A K, Marsh S, Murry D J, Hurley T D, McLeod H L

Abstract excerpt

Significant variability in the antitumor efficacy and systemic toxicity of gemcitabine has been observed in cancer patients. However, there are currently no tools for prospective identification of patients at risk for untoward events. This study has identified and validated single-nucleotide poly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Chi-Square Distribution
Share to Databases, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Gemcitabine

Share to Gene Frequency

Share to Genetic Variation

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 15224082
DOI: 10.1038/sj.tpj.6500259

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15224082-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.PMID 15224082Read ↗

Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.Semantic proximity Read ↗

Clinical pharmacology and pharmacogenetics of gemcitabineSemantic proximity Read ↗

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.Semantic proximity Read ↗

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.Semantic proximity Read ↗

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?Semantic proximity Read ↗

Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.Semantic proximity Read ↗

Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.Semantic proximity Read ↗

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Semantic proximity Read ↗

Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population.Semantic proximity Read ↗

A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.Semantic proximity Read ↗

Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine.Semantic proximity Read ↗

Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.